

Nadia Harbeck

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7058544/nadia-harbeck-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

222
papers

15,390
citations

54
h-index

123
g-index

244
ext. papers

20,902
ext. citations

8.9
avg, IF

6.73
L-index

#	Paper	IF	Citations
222	ABC6 Consensus: Assessment by a Group of German Experts.. <i>Breast Care</i> , 2022 , 17, 90-100	2.4	0
221	The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples.. <i>Nature Communications</i> , 2022 , 13, 449	17.4	5
220	Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.. <i>New England Journal of Medicine</i> , 2022 , 386, 556-567	59.2	29
219	Awareness and Availability of Routine Germline Mutation Testing in Patients with Advanced Breast Cancer in Germany.. <i>Breast Care</i> , 2022 , 17, 40-46	2.4	1
218	Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2- advanced breast cancer.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 17588359221081203	5.4	1
217	Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock.. <i>Genome Biology</i> , 2022 , 23, 52	18.3	0
216	Increased risk for thromboembolic events from combination of a gynecologic malignancy with severe acute respiratory syndrome coronavirus 2 infection: a case report.. <i>Journal of Medical Case Reports</i> , 2022 , 16, 119	1.2	0
215	Gene signatures in patients with early breast cancer and relapse despite pathologic complete response.. <i>Npj Breast Cancer</i> , 2022 , 8, 42	7.8	1
214	Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102759	2.2	2
213	A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer.. <i>Cancer</i> , 2022 , 128 Suppl 11, 2209-2223	6.4	0
212	Update Breast Cancer 2022 Part 1 Early Stage Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2022 , 82, 580-589	2	
211	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. <i>Journal of Clinical Oncology</i> , 2021 , JCO2100896	2.2	3
210	Phenotype Discordance between Primary Tumor and Metastasis Impacts Metastasis Site and Outcome: Results of WSG-DETECT-PriMet. <i>Breast Care</i> , 2021 , 16, 475-483	2.4	1
209	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology, The</i> , 2021 , 22, 1669-1680	21.7	20
208	Quality-of-life methodology in hormone receptor-positive advanced breast cancer: Current tools and perspectives for the future. <i>Cancer Treatment Reviews</i> , 2021 , 102, 102321	14.4	1
207	Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry. <i>JAMA Oncology</i> , 2021 ,	13.4	13
206	Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. <i>Npj Breast Cancer</i> , 2021 , 7, 145	7.8	0

205	TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer. <i>Cancer Medicine</i> , 2021 , 10, 8581-8594	4.8	3
204	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211053416	5.4	0
203	Risk-adapted adjuvant therapy of luminal early breast cancer in 2020. <i>Current Opinion in Obstetrics and Gynecology</i> , 2021 , 33, 53-58	2.4	2
202	Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials. <i>Breast Cancer Research</i> , 2021 , 23, 36	8.3	0
201	Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score 2021 , 9,		11
200	Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy: VinoMetro-AGO-B-046. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 3391-3400	4.9	1
199	Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting. <i>Diagnostics</i> , 2021 , 11,	3.8	3
198	Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 499-511	21.7	68
197	Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer Patients. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021 , 81, 469-480	2	3
196	Neoadjuvant and adjuvant end-points in health technology assessment in oncology. <i>European Journal of Cancer</i> , 2021 , 147, 40-50	7.5	1
195	Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial 2021 , 9,		4
194	Pathological complete response rate and survival in patients with BRCA-associated triple-negative breast cancer after 12 weeks of de-escalated neoadjuvant chemotherapy: Translational results of the WSG-ADAPT TN randomized phase II trial (NCT01815242).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 570-579	2.2	2
193	Reply to K. Hashimoto and A. Shimomura. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1507-1508	2.2	
192	De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 503-503	2.2	5
191	Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2- chemotherapy trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 504-504	2.2	1
190	Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study. <i>European Journal of Cancer</i> , 2021 , 150, 268-277	7.5	2
189	Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 2535-2544	4.9	3
188	CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies. <i>Future Oncology</i> , 2021 , 17, 2107-2122	3.6	10

187	Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3. <i>Oncologist</i> , 2021 , 26, e1339-e1346	5.7	5
186	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021 , 11, 2796-2811	24.4	10
185	Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients. <i>Breast Care</i> , 2021 , 16, 50-58	2.4	1
184	Post-Neoadjuvant Gemcitabine and Cisplatin with Regional Hyperthermia for Patients with Triple-Negative Breast Cancer and Non-pCR after Neoadjuvant Chemotherapy: A Single-Institute Experience. <i>Breast Care</i> , 2021 , 16, 173-180	2.4	1
183	Late Presentation at Primary Diagnosis of Breast Cancer: Patients' Personality Characteristics and Attitudes. <i>Breast Care</i> , 2021 , 16, 343-349	2.4	
182	First Experiences with Alpelisib in Clinical Routine: Case Reports from a German Breast Center. <i>Breast Care</i> , 2021 , 16, 129-134	2.4	1
181	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211042224	5.4	3
180	St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer. <i>Breast Care</i> , 2021 , 16, 135-143	2.4	29
179	Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. <i>JCO Global Oncology</i> , 2021 , 7, 162-172	3.7	16
178	Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials. <i>International Journal of Cancer</i> , 2021 , 148, 2614	7.5	3
177	Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. <i>Clinical Cancer Research</i> , 2021 , 27, 5607-5618	12.9	0
176	Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 6156-6163	12.9	1
175	Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3541-3545	2.2	2
174	Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT. <i>European Journal of Radiology</i> , 2021 , 141, 109821	4.7	3
173	Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	2
172	Molecular Prognostic Factors for Distant Metastases in Premenopausal Patients with HR+/HER2- Early Breast Cancer. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	2
171	Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	1
170	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2

169	Changes in gynecologic and breast cancer diagnoses during the first wave of the COVID-19 pandemic: analysis from a tertiary academic gynecological center in Germany. <i>Archives of Gynecology and Obstetrics</i> , 2021 , 1	2.5	0
168	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. <i>Clinical Cancer Research</i> , 2021 , 27, 6307-6313	12.9	0
167	Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. <i>European Journal of Cancer</i> , 2021 , 154, 128-137	7.5	5
166	Update Mammakarzinom 2020 Teil 5 Einführung von Substanzen aus der metastasierten Therapiesituation in die frühe Therapiesituation. <i>Senologie - Zeitschrift für Mammadiagnostik Und -therapie</i> , 2021 , 18, 254-265	0	
165	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021 , 32, 1216-1235	10.3	44
164	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. <i>Breast Care</i> , 2021 , 16, 228-235	2.4	7
163	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. <i>Breast Care</i> , 2021 , 16, 214-227	2.4	19
162	Distress in hospitalized cancer patients: Associations with personality traits, clinical and psychosocial characteristics. <i>Psycho-Oncology</i> , 2021 ,	3.9	1
161	Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2021 ,	5.3	2
160	European Breast Cancer Conference 12, October 2-3, 2020: Interview with the Chairs. <i>Breast Care</i> , 2020 , 15, 594-598	2.4	
159	Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic. <i>Npj Breast Cancer</i> , 2020 , 6, 21	7.8	24
158	International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts. <i>Breast Care</i> , 2020 , 15, 82-95	2.4	20
157	2. Therapie des metastasierten Mammakarzinoms 2020 , 71-120		
156	Cytoplasmic PPAR α is a marker of poor prognosis in patients with Cox-1 negative primary breast cancers. <i>Journal of Translational Medicine</i> , 2020 , 18, 94	8.5	7
155	Pembrolizumab for Early Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 810-821	59.2	599
154	Enhancing global access to cancer medicines. <i>Ca-A Cancer Journal for Clinicians</i> , 2020 , 70, 105-124	220.7	63
153	Cytoplasmic and Nuclear Forms of Thyroid Hormone Receptor β Are Inversely Associated with Survival in Primary Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	5
152	Breast cancer is a systemic disease optimally treated by a multidisciplinary team. <i>Nature Reviews Disease Primers</i> , 2020 , 6, 30	51.1	11

151	Abstract PD5-10: Impact of immune markers on response to neoadjuvant de-escalated T-DM1 or trastuzumab with/or without endocrine therapy in HR+/HER2+ early breast cancer: A translational subproject of the WSG-ADAPT-HER2+/HR+ trial 2020 ,		2
150	Heart sparing radiotherapy in breast cancer: the importance of baseline cardiac risks. <i>Radiation Oncology</i> , 2020 , 15, 117	4.2	4
149	De-escalated chemotherapy versus endocrine therapy plus pertuzumab+ trastuzumab for HR+/HER2+ early breast cancer (BC): First efficacy results from the neoadjuvant WSG-TP-II study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 515-515	2.2	5
148	A Web- and App-Based Connected Care Solution for COVID-19 In- and Outpatient Care: Qualitative Study and Application Development. <i>JMIR Public Health and Surveillance</i> , 2020 , 6, e19033	11.4	27
147	ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy (ADAPT) comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS601-TPS601	2.2	4
146	Association of T- and B-cell receptor repertoires with molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 511-511	2.2	
145	Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 110-121	12.9	57
144	Metastatic Breast Cancer: Is There a Differential Therapy Efficacy between Visceral and Non-Visceral Metastatic Breast Cancer?. <i>Breast Care</i> , 2020 , 15, 527-533	2.4	
143	mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. <i>Cancers</i> , 2020 , 12,	6.6	9
142	The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920973130	5.4	9
141	Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. <i>Cancer Discovery</i> , 2020 ,	24.4	96
140	Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7). <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920973130	5.4	16
139	Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2020 , 396, 1090-1100	4.0	232
138	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). <i>Journal of Clinical Oncology</i> , 2020 , 38, 3987-3998	2.2	152
137	Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial. <i>International Journal of Cancer</i> , 2020 , 146, 262-271	7.5	17
136	EVA-Scalp: Evaluation of Patient Satisfaction with a Scalp Cooling Device to Prevent Chemotherapy-Induced Alopecia in Breast Cancer Patients. <i>Breast Care</i> , 2020 , 15, 171-177	2.4	3
135	Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial. <i>Clinical Breast Cancer</i> , 2020 , 20, 439-447	3	1
134	A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER HER2 Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 4242-4249	12.9	13

133	Breast cancer. <i>Nature Reviews Disease Primers</i> , 2019 , 5, 66	51.1	698
132	Prognostic relevance of RIP140 and ER α expression in unifocal versus multifocal breast cancers: a preliminary report. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	7
131	Mastectomy or Breast-Conserving Therapy for Early Breast Cancer in Real-Life Clinical Practice: Outcome Comparison of 7565 Cases. <i>Cancers</i> , 2019 , 11,	6.6	31
130	Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2206-2216	2.2	78
129	Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. <i>New England Journal of Medicine</i> , 2019 , 381, 307-316	59.2	384
128	Safety analysis of proposed pegfilgrastim biosimilar in Phase I and Phase III studies. <i>Future Oncology</i> , 2019 , 15, 1313-1322	3.6	6
127	CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib. <i>BioDrugs</i> , 2019 , 33, 125-135	7.9	40
126	The Prognostic Impact of the Aryl Hydrocarbon Receptor (AhR) in Primary Breast Cancer Depends on the Lymph Node Status. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	12
125	Thyronamine regulation of TAAR1 expression in breast cancer cells and investigation of its influence on viability and migration. <i>Breast Cancer: Targets and Therapy</i> , 2019 , 11, 87-97	3.9	9
124	St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment. <i>Breast Care</i> , 2019 , 14, 103-110	2.4	84
123	West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 799-808	2.2	41
122	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019 , 393, 1440-1452	40	137
121	Pattern of care of adjuvant radiotherapy in male breast cancer patients in clinical practice: an observational study. <i>Strahlentherapie Und Onkologie</i> , 2019 , 195, 289-296	4.3	4
120	Does deep inspiration breath-hold prolong life? Individual risk estimates of ischaemic heart disease after breast cancer radiotherapy. <i>Radiotherapy and Oncology</i> , 2019 , 131, 202-207	5.3	35
119	The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. <i>European Journal of Cancer</i> , 2019 , 118, 1-9	7.5	8
118	Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 500-500	2.2	4
117	First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial. <i>Cancer Management and Research</i> , 2019 , 11, 10427-10433	3.6	2
116	Emerging strategies in neoadjuvant treatment of patients with HER2-positive early breast cancer. <i>Breast</i> , 2019 , 48 Suppl 1, S97-S102	3.6	6

115	Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019 , 174, 453-461	4.4	7
114	Truly personalized therapy - an end to the era of one size fits all. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 77-78	19.4	5
113	Recover your smile: Effects of a beauty care intervention on depressive symptoms, quality of life, and self-esteem in patients with early breast cancer. <i>Psycho-Oncology</i> , 2019 , 28, 401-407	3.9	13
112	PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients. <i>International Journal of Oncology</i> , 2018 , 52, 755-767	4.4	12
111	Epigenome-based cancer risk prediction: rationale, opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 292-309	19.4	72
110	ABC4 Consensus: Assessment by a German Group of Experts. <i>Breast Care</i> , 2018 , 13, 48-58	2.4	6
109	The safety of palbociclib for the treatment of advanced breast cancer. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 325-330	4.1	2
108	Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies. <i>Oncologist</i> , 2018 , 23, 403-409	5.7	7
107	Role of postoperative radiotherapy in reducing ipsilateral recurrence in DCIS: an observational study of 1048 cases. <i>Radiation Oncology</i> , 2018 , 13, 25	4.2	8
106	Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. <i>Clinical Cancer Research</i> , 2018 , 24, 3079-3086	12.9	9
105	Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study. <i>Clinical Breast Cancer</i> , 2018 , 18, 175-183	3	11
104	Evaluation of Reproductive Concerns and Biographical Impact of Breast Cancer in Young Patients. <i>Breast Care</i> , 2018 , 13, 126-130	2.4	1
103	Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial. <i>Journal of Geriatric Oncology</i> , 2018 , 9, 163-169	3.6	6
102	Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. <i>European Journal of Cancer</i> , 2018 , 101, 123-133	7.5	34
101	Importance of RIP140 and LCoR Sub-Cellular Localization for Their Association With Breast Cancer Aggressiveness and Patient Survival. <i>Translational Oncology</i> , 2018 , 11, 1090-1096	4.9	10
100	Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells-Results From the SUCCESS A Trial. <i>Clinical Breast Cancer</i> , 2018 , 18, e1103-e1110	3	
99	EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer. <i>BMC Cancer</i> , 2018 , 18, 431	4.8	13
98	Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, e181564	13.4	8

97	Phase III study of tasisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.. <i>Journal of Clinical Oncology</i> , 2018 , 36, LBA1006-LBA1006	2.2	99
96	Mammakarzinom bei der alten und geriatrischen Patientin 2018 , 401-416		
95	Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 115-126	21.7	203
94	Induction of apoptosis in breast cancer cells in vitro by Fas ligand reverse signaling. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 249-256	4.9	12
93	Advances in targeting HER2-positive breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2018 , 30, 55-59	2.4	24
92	Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers. <i>BMC Medical Genomics</i> , 2018 , 11, 80	3.7	7
91	Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 1926-1936	59.2	478
90	Recent Developments in Radiation Oncology: An Overview of Individualised Treatment Strategies in Breast Cancer. <i>Breast Care</i> , 2018 , 13, 285-291	2.4	11
89	Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 904-915	21.7	400
88	Genexpressionsanalysen bei Patientinnen mit frhem Brustkrebs. <i>Best Practice Onkologie</i> , 2018 , 13, 24-30		
87	Prognostic impact of residual disease in simultaneous additional excision specimens after one-step breast conserving therapy with negative final margin status in primary breast cancer. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 1318-1323	3.6	6
86	Neoadjuvant radiotherapy followed by mastectomy and immediate breast reconstruction : An alternative treatment option for locally advanced breast cancer. <i>Strahlentherapie Und Onkologie</i> , 2017 , 193, 324-331	4.3	12
85	Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , 143, 1701-1712	4.9	23
84	Increased trace amine-associated receptor 1 (TAAR1) expression is associated with a positive survival rate in patients with breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , 143, 1637-1647	4.9	16
83	St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment. <i>Breast Care</i> , 2017 , 12, 102-107	2.4	87
82	Influence of vitamin D signaling on hormone receptor status and HER2 expression in breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , 143, 1107-1122	4.9	15
81	Genexpressionsanalysen bei Patientinnen mit frhem Brustkrebs. <i>Gynkologie + Geburtshilfe</i> , 2017 , 22, 32-38	0	
80	RE: Post-traumatic Stress as the Primary Cause for Cognitive Decline-Not the Whole Story, and Perhaps No Story at All. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	1

79	De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Impact of Etoposide on BRCA1 Expression in Various Breast Cancer Cell Lines. <i>Drugs in R and D</i> , 2017 , <i>17</i> , 569-583	2.2	72
78	ET (Etoposide) Therapy (ET) Versus Trastuzumab Plus ET. <i>Journal of Clinical Oncology</i> , 2017 , <i>35</i> , 3040-3054	3.4	1
77	LKB1 pro-oncogenic activity triggers cell survival in circulating tumor cells. <i>Molecular Oncology</i> , 2017 , <i>11</i> , 1508-1526	7.9	14
76	15. Internationale St.-Gallen-Konsensus-Konferenz: Behandlung des frühen Mammakarzinoms. <i>Onkologe</i> , 2017 , <i>23</i> , 666-677	0.1	
75	Neoadjuvant therapy for triple negative and HER2-positive early breast cancer. <i>Breast</i> , 2017 , <i>34</i> Suppl 1, S99-S103	3.6	33
74	The safety and efficacy of palbociclib in the treatment of metastatic breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2017 , <i>17</i> , 661-668	3.5	8
73	Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. <i>Breast Cancer Research and Treatment</i> , 2017 , <i>165</i> , 573-583	4.4	100
72	Breast cancer. <i>Lancet, The</i> , 2017 , <i>389</i> , 1134-1150	4.0	923
71	Survival of de novo stage IV breast cancer patients over three decades. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , <i>143</i> , 509-519	4.9	21
70	A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. <i>Breast Cancer Research and Treatment</i> , 2017 , <i>161</i> , 63-72	4.4	22
69	Trends in use and outcome of postoperative radiotherapy following mastectomy: A population-based study. <i>Radiotherapy and Oncology</i> , 2017 , <i>122</i> , 2-10	5.3	11
68	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. <i>JAMA Oncology</i> , 2017 , <i>3</i> , 227-234	13.4	79
67	eHealth solutions for therapy management in oncology. <i>Breast Cancer Management</i> , 2017 , <i>6</i> , 101-106	0.7	5
66	Fluorescence Analysis of Vitamin D Receptor Status of Circulating Tumor Cells (CTCS) in Breast Cancer: From Cell Models to Metastatic Patients. <i>International Journal of Molecular Sciences</i> , 2017 , <i>18</i> ,	6.3	4
65	Mammakarzinom bei der alten und geriatrischen Patientin 2017 , 1-16		
64	Palbociclib and Letrozole in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016 , <i>375</i> , 1925-1936	19.36	1278
63	HER2-positive breast cancer: neoadjuvant and adjuvant therapy 2016 , 29-49		
62	Response. <i>Journal of the National Cancer Institute</i> , 2016 , <i>108</i> ,	9.7	1

61	West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2341-9	2.2	185
60	Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1034-42	2.2	254
59	PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2 ⁺ advanced breast cancer (ABC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 507-507	2.2	58
58	eHealth in Modern Patient-Caregiver Communication: High Rate of Acceptance Among Physicians for Additional Support of Breast Cancer Patients During Long-Term Therapy. <i>JMIR Cancer</i> , 2016 , 2, e14	3.2	8
57	EHealth Acceptance and New Media Preferences for Therapy Assistance Among Breast Cancer Patients. <i>JMIR Cancer</i> , 2016 , 2, e13	3.2	17
56	Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. <i>Future Oncology</i> , 2016 , 12, 1359-67	3.6	29
55	Local Resection of Primary Tumor in Upfront Stage IV Breast Cancer. <i>Breast Care</i> , 2016 , 11, 411-417	2.4	3
54	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet Oncology</i> , 2016 , 17, 425-433	21.7	931
53	Evolving psychosocial, emotional, functional, and support needs of women with advanced breast cancer: Results from the Count Us, Know Us, Join Us and Here & Now surveys. <i>Breast</i> , 2016 , 28, 5-12	3.6	38
52	A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.	5.7	32
51	Thyroid Hormones and Vitamin D in Patients with Breast Cancer with Mutations in BRCA1 or BRCA2 Genes. <i>Anticancer Research</i> , 2016 , 36, 3185-90	2.3	
50	OVSCORE - a validated score to identify ovarian cancer patients not suitable for primary surgery. <i>Oncology Letters</i> , 2015 , 9, 418-424	2.6	11
49	St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion. <i>Breast Care</i> , 2015 , 10, 124-30	2.4	61
48	Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015 , 26, 1533-46	10.3	1122
47	Elucidating pretreatment cognitive impairment in breast cancer patients: the impact of cancer-related post-traumatic stress. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	51
46	Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications. <i>Breast</i> , 2015 , 24 Suppl 2, S44-8	3.6	18
45	Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. <i>Science Translational Medicine</i> , 2015 , 7, 315ra188	17.5	177
44	Adjuvant radiotherapy after breast conserving surgery - a comparative effectiveness research study. <i>Radiotherapy and Oncology</i> , 2015 , 114, 28-34	5.3	24

43	Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. <i>Trials</i> , 2015 , 16, 575	2.8	20
42	Breast Cancer Is Our Global Responsibility. <i>Breast Care</i> , 2015 , 10, 360	2.4	5
41	Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2015 , 373, 209-19	59.2	940
40	SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015 , 154, 351-7	4.4	25
39	High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. <i>Clinical Cancer Research</i> , 2015 , 21, 569-76	12.9	58
38	PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1334-9	2.2	164
37	First international consensus guidelines for breast cancer in young women (BCY1). <i>Breast</i> , 2014 , 23, 209-26	3.6	108
36	Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow. <i>Cancer Treatment Reviews</i> , 2014 , 40, 434-44	14.4	73
35	uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. <i>Breast Cancer Research</i> , 2014 , 16, 428	8.3	157
34	Afatinib in the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014 , 23, 1039-47	5.9	25
33	Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1437-44	2.2	63
32	Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective. <i>Breast Care</i> , 2014 , 9, 52-9	2.4	6
31	Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. <i>Clinical Cancer Research</i> , 2014 , 20, 456-68	12.9	122
30	Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2750-7	2.2	81
29	Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck. <i>Future Oncology</i> , 2014 , 10, 21-40	3.6	11
28	Oncotype DX and proliferation response to short-term preoperative endocrine therapy for chemotherapy decision in early breast cancer: Biomarker data from the prospective multicenter phase II/III WSG-ADAPT trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 524-524	2.2	1
27	Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations. <i>Drugs</i> , 2013 , 73, 1665-80	12.1	6
26	WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. <i>Trials</i> , 2013 , 14, 261	2.8	69

25	Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 138, 839-90	4.4	17
24	St. Gallen 2013: brief preliminary summary of the consensus discussion. <i>Breast Care</i> , 2013 , 8, 102-9	2.4	84
23	German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3531-9	2.2	72
22	A randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine versus capecitabine monotherapy in first-line HER2-negative metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 508-508	2.2	2
21	A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(+) breast cancer who have not received any prior systemic anticancer treatment for advanced disease.. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS652-TPS652	2.2	6
20	Early prediction of efficacy of endocrine therapy in breast cancer (BC): Pilot study and validation with 18F fluoroestradiol (18F-FES) PET/CT.. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS649-TPS649	2.2	
19	Treatment of breast cancer during pregnancy: an observational study. <i>Lancet Oncology, The</i> , 2012 , 13, 887-96	21.7	177
18	A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 1149-59	4.4	59
17	Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 237-46	4.4	72
16	ABC1 Consensus Conference - a German Perspective: First International Consensus Conference on Advanced Breast Cancer (ABC1), Lisbon, November 5, 2011. <i>Breast Care</i> , 2012 , 7, 52-59	2.4	5
15	Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2011 , 47, 2273-81	7.5	132
14	Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6HEC versus 3HEC/3Docetaxel. <i>BMC Cancer</i> , 2011 , 11, 140	4.8	37
13	Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3351-7	2.2	383
12	St. Gallen 2011: Summary of the Consensus Discussion. <i>Breast Care</i> , 2011 , 6, 136-141	2.4	156
11	Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2874-80	2.2	158
10	Personalized treatment of early-stage breast cancer: present concepts and future directions. <i>Cancer Treatment Reviews</i> , 2010 , 36, 584-94	14.4	40
9	Angiogenesis inhibitors in the management of breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2010 , 22, 79-86	2.4	14
8	Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 1028-9	9.7	29

7	The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. <i>Breast Cancer Research and Treatment</i> , 2009 , 116, 303-9	4.4	123
6	Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1665-71	2.2	299
5	Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 116-28	9.7	488
4	Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). <i>Cancer Research</i> , 2002 , 62, 4617-22	10.1	124
3	Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. <i>Journal of the National Cancer Institute</i> , 2001 , 93, 913-20	9.7	360
2	A Web- and App-Based Connected Care Solution for COVID-19 In- and Outpatient Care: Qualitative Study and Application Development (Preprint)		2
1	Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference. <i>Breast Care</i> , 1-10	2.4	